NCT06109207 2024-07-23
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
West China Hospital
Phase 1 Recruiting
Clinical Trials
4 trialsNCT04393506 2023-11-22
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 1 Completed
NCT03121716 2022-07-12
A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT04510818 2020-08-14
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)
Ruijin Hospital
Phase 1 Unknown